ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Has Average Target Price of $31.34 According to Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on ACADIA Pharmaceuticals, with 13 buy ratings and five holds among 18 analysts. The average 12-month price target is $31.34, well above the reported share price of $18.62.
• ACADIA reported quarterly adjusted earnings of $0.18 per share, exceeding the $0.07 consensus estimate, while revenue of $308 million rose 16.4% year over year. Nuplazid and Daybue continue to support growth, though competition remains a risk.
• The stock has weakened sharply, trading near its 52-week low; UBS recently downgraded it to Neutral and cut its target to $23 from $49. Insiders sold approximately $1.02 million of shares in the last quarter, while institutional investors own 96.71% of the company.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eighteen analysts that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $31.34.

A number of equities analysts have commented on the stock. Citigroup restated a "buy" rating and issued a $33.00 target price (down from $40.00) on shares of ACADIA Pharmaceuticals in a research note on Friday, September 25th. TD Cowen reaffirmed a "buy" rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 24th. William Blair set a $33.00 price target on shares of ACADIA Pharmaceuticals in a research note on Monday, September 28th. Needham & Company LLC lowered their price target on ACADIA Pharmaceuticals from $41.00 to $35.00 and set a "buy" rating for the company in a report on Friday, September 25th. Finally, Morgan Stanley increased their price objective on ACADIA Pharmaceuticals from $27.00 to $28.00 and gave the stock an "equal weight" rating in a research note on Tuesday, August 25th.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Elizabeth Thompson sold 16,558 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the sale, the executive vice president directly owned 18,994 shares of the company's stock, valued at approximately $496,313.22. This represents a 46.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Mark C. Schneyer sold 14,292 shares of the business's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $29.22, for a total value of $417,612.24. Following the transaction, the executive vice president owned 67,828 shares in the company, valued at approximately $1,981,934.16. This trade represents a 17.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 36,699 shares of company stock valued at $1,019,894 over the last quarter. Company insiders own 26.20% of the company's stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ACAD. GAMMA Investing LLC increased its stake in ACADIA Pharmaceuticals by 15.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 402 shares in the last quarter. Cim Investment Management Inc. raised its holdings in ACADIA Pharmaceuticals by 7.3% during the second quarter. Cim Investment Management Inc. now owns 15,273 shares of the biopharmaceutical company's stock worth $386,000 after purchasing an additional 1,034 shares during the last quarter. Swiss National Bank boosted its position in ACADIA Pharmaceuticals by 0.6% during the first quarter. Swiss National Bank now owns 234,404 shares of the biopharmaceutical company's stock worth $5,218,000 after purchasing an additional 1,500 shares in the last quarter. Nykredit A S acquired a new stake in ACADIA Pharmaceuticals in the second quarter valued at $38,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in ACADIA Pharmaceuticals in the second quarter valued at $50,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Stock Down 4.1%

ACAD opened at $18.62 on Wednesday. The business has a fifty day moving average of $26.09 and a 200 day moving average of $24.08. ACADIA Pharmaceuticals has a 52-week low of $18.39 and a 52-week high of $30.96. The stock has a market cap of $3.21 billion, a P/E ratio of 8.39 and a beta of 0.88.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. The business had revenue of $308.00 million during the quarter, compared to the consensus estimate of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%. The business's revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period last year, the company earned $0.16 earnings per share. Equities analysts anticipate that ACADIA Pharmaceuticals will post 0.64 EPS for the current fiscal year.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Nuplazid and Daybue continue to support ACADIA’s revenue growth. Potential upside opportunities include increasing demand, additional formulations and European expansion, although competition remains a risk. Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
• Negative Sentiment: UBS downgraded ACADIA Pharmaceuticals from Buy to Neutral and cut its price target to $23 from $49. Although the new target still implies potential upside from approximately $18.62, the steep reduction signals materially weaker confidence in the stock’s risk-reward profile and was the primary reason for the decline. UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of ACADIA investors. The announcement does not establish wrongdoing, but securities-law investigations can add reputational and legal uncertainty and weigh on investor sentiment. Pomerantz Investor Alert Regarding ACADIA Pharmaceuticals
• Negative Sentiment: The stock reached a new 52-week low near $19.01, reinforcing the technical weakness and suggesting continued selling pressure after the UBS downgrade. Acadia Pharmaceuticals Stock Hits 52-Week Low

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company is headquartered in San Diego, California, and serves patients and healthcare providers primarily in the United States.

ACADIA's commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.